secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2025-07-23T23:59:59+00:00
Accession:  0000885725-25-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific Q2 net sales $5.06B (+22.8% reported); adj. EPS $0.75 beat guidance; raises FY outlook
--------------------------------------------------------------------------------

- GAAP EPS $0.53 ($797M net income) vs $0.22 a year ago; adjusted EPS $0.75 vs guidance $0.71-0.73.
- Q2 organic net sales growth 17.4% (guidance 13-15%); US sales up 30.7% reported.
- Cardiovascular segment grew 26.8% reported; MedSurg up 15.7% reported.
- FY2025 guidance raised: organic growth 14-15%; adjusted EPS $2.95-2.99 (prior $2.82-2.87).
- Closed acquisitions of Intera Oncology and SoniVie; received expanded FDA label for FARAPULSE PFA System.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572525000039/0000885725-25-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572525000039/bsx-20250723.htm
  HTML page:      https://secwatch.observer/filing/0000885725-25-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer